Hirte, H.; Poon, R.; Yao, X.; May, T.; Ethier, J.-L.; Petz, L.; Speakman, J.; Elit, L.
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Curr. Oncol. 2022, 29, 231-242.
https://doi.org/10.3390/curroncol29010022
AMA Style
Hirte H, Poon R, Yao X, May T, Ethier J-L, Petz L, Speakman J, Elit L.
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology. 2022; 29(1):231-242.
https://doi.org/10.3390/curroncol29010022
Chicago/Turabian Style
Hirte, Hal, Raymond Poon, Xiaomei Yao, Taymaa May, Josee-Lyne Ethier, Lauri Petz, Jane Speakman, and Laurie Elit.
2022. "Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline" Current Oncology 29, no. 1: 231-242.
https://doi.org/10.3390/curroncol29010022
APA Style
Hirte, H., Poon, R., Yao, X., May, T., Ethier, J.-L., Petz, L., Speakman, J., & Elit, L.
(2022). Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology, 29(1), 231-242.
https://doi.org/10.3390/curroncol29010022
